Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Imaging Biol ; 18(1): 117-26, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26013478

ABSTRACT

PURPOSE: The first biological evaluation of two potent fluorine-18 radiolabelled inhibitors of caspase-3/7 was achieved in a cerebral stroke rat model to visualize apoptosis. PROCEDURES: In vivo characteristics of isatins [(18)F]-2 and [(18)F]-3 were studied and compared by µPET to previously described 1-[4-(2-[(18)F]fluoroethyl)benzyl]-5-(2-methoxymethylpyrrolidin-1-ylsulfonyl)isatin ([(18)F]-1) and to 2-(5-[(18)F]fluoropentyl)-2-methyl-malonic acid ([(18)F]ML-10) used as a reference radiotracer in a rat stroke model. RESULTS: [(18)F]-2 and [(18)F]-3 were radiolabelled with high radiochemical purity and high specific radioactivity. Radioactivity uptakes in ischemic and contralateral brain regions were weak for the three radiolabelled isatins and lower for [(18)F]ML-10. In µPET, time activity curves showed significant uptake differences between both regions of interest for [(18)F]-1 after 45 min. No differences were observed for [(18)F]ML-10. CONCLUSIONS: Radiolabelled isatins are more promising radiotracers to image apoptosis than [(18)F]ML-10 in this stroke animal model without craniectomy. In particular, [(18)F]-1 presented significant uptake in apoptotic area 45 min after administration.


Subject(s)
Apoptosis/drug effects , Caspase 3/metabolism , Caspase 7/metabolism , Caspase Inhibitors/pharmacology , Methylmalonic Acid/analogs & derivatives , Molecular Imaging/methods , Radiopharmaceuticals/pharmacology , Stroke/diagnostic imaging , Animals , Caspase Inhibitors/blood , Caspase Inhibitors/pharmacokinetics , Disease Models, Animal , Isatin/chemistry , Isatin/pharmacology , Male , Methylmalonic Acid/pharmacokinetics , Methylmalonic Acid/pharmacology , Radionuclide Imaging , Radiopharmaceuticals/blood , Radiopharmaceuticals/pharmacokinetics , Rats, Sprague-Dawley , Stroke/pathology , Tissue Distribution/drug effects
2.
J Labelled Comp Radiopharm ; 56(5): 289-94, 2013 May 15.
Article in English | MEDLINE | ID: mdl-24285373

ABSTRACT

Microfluidics technology has emerged as a powerful tool for the radiosynthesis of positron emission tomography (PET) and single-photon emission computed tomography radiolabeled compounds. In this work, we have exploited a continuous flow microfluidic system (Advion, Inc., USA) for the [(18) F]-fluorine radiolabeling of the malonic acid derivative, [(18) F] 2-(5-fluoro-pentyl)-2-methyl malonic acid ([(18) F]-FPMA), also known as [(18) F]-ML-10, a radiotracer proposed as a potential apoptosis PET imaging agent. The radiosynthesis was developed using a new tosylated precursor. Radiofluorination was initially optimized by manual synthesis and served as a basis to optimize reaction parameters for the microfluidic radiosynthesis. Under optimized conditions, radio-thin-layer chromatography analysis showed 79% [(18) F]-fluorine incorporation prior to hydrolysis and purification. Following hydrolysis, the [(18) F]-FPMA was purified by C18 Sep-Pak, and the final product was analyzed by radio-HPLC (high-performance liquid chromatography). This resulted in a decay-corrected 60% radiochemical yield and ≥98% radiochemical purity. Biodistribution data demonstrated rapid blood clearance with less than 2% of intact [(18) F]-FPMA radioactivity remaining in the circulation 60 min post-injection. Most organs showed low accumulation of the radiotracer, and radioactivity was predominately cleared through kidneys (95% in 1 h). Radio-HPLC analysis of plasma and urine samples showed a stable radiotracer at least up to 60 min post-injection.


Subject(s)
Isotope Labeling/methods , Methylmalonic Acid/analogs & derivatives , Microfluidics/methods , Radiopharmaceuticals/chemical synthesis , Animals , Fluorine Radioisotopes/chemistry , Fluorine Radioisotopes/pharmacokinetics , Methylmalonic Acid/chemical synthesis , Methylmalonic Acid/pharmacokinetics , Mice , Mice, Nude , Radiopharmaceuticals/pharmacokinetics , Tissue Distribution
3.
J Nucl Med ; 52(5): 720-5, 2011 May.
Article in English | MEDLINE | ID: mdl-21498526

ABSTRACT

UNLABELLED: Clinical PET of apoptosis may have substantial value in advancing patient care. We report here the first-in-humans study with (18)F-labeled 2-(5-fluoropentyl)-2-methyl malonic acid ((18)F-ML-10), a small-molecule PET tracer for apoptosis. Presented are the dosimetry, biodistribution, stability, and safety profiles of this PET tracer in healthy human volunteers. Also reported is tracer binding to targeted apoptotic cells in testicular tissue, where a relative abundance of apoptotic cells is normally observed. METHODS: (18)F-ML-10 (233 ± 90 MBq) was intravenously administered to 8 healthy subjects, followed by whole-body PET/CT for 220 min. Serial blood and urine samples were collected for radioactivity measurement, and plasma tracer stability was assessed by high-performance liquid chromatography. Dosimetry calculations were performed using OLINDA/EXM software. RESULTS: (18)F-ML-10 manifested high stability in vivo and rapid distribution followed by fast clearance, with an elimination half-life of 1.3 ± 0.1 and 1.1 ± 0.2 h from the blood and from all other organs, respectively, and excretion through the urine. Dosimetry showed an average effective whole-body dose of 15.4 ± 3.7 µSv/MBq, with the urinary bladder being the dose-limiting organ. Selective accumulation and retention of the tracer in the testes was observed in all male subjects, a finding also demonstrated in mice using both small-animal PET and histopathology, confirming binding to apoptotic cells. Administration of (18)F-ML-10 was safe, without adverse effects. CONCLUSION: (18)F-ML-10 administered to healthy humans demonstrated a favorable dosimetry, biodistribution, stability, and safety profile. Binding to apoptotic sites was also demonstrated. These data support further development of this small-molecule probe for clinical PET of apoptosis.


Subject(s)
Apoptosis , Methylmalonic Acid/analogs & derivatives , Positron-Emission Tomography/methods , Adult , Animals , Biological Transport , Drug Stability , Female , Humans , Male , Methylmalonic Acid/adverse effects , Methylmalonic Acid/metabolism , Methylmalonic Acid/pharmacokinetics , Mice , Mice, Inbred BALB C , Radioactive Tracers , Radiometry , Safety , Spermatogenesis , Testis/cytology , Testis/metabolism , Young Adult
4.
J Nucl Med ; 49(9): 1520-8, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18703595

ABSTRACT

UNLABELLED: Clinical molecular imaging of apoptosis is a highly desirable yet unmet challenge. Here we provide the first report on (18)F-labeled 5-fluoropentyl-2-methyl-malonic acid ((18)F-ML-10), a small-molecule, (18)F-labeled PET tracer for the imaging of apoptosis in vivo; this report includes descriptions of the synthesis, radiolabeling, and biodistribution of this novel apoptosis marker. We also describe the use of (18)F-ML-10 for small-animal PET of neurovascular cell death in experimental cerebral stroke in mice. METHODS: (18)F-ML-10 was synthesized by nucleophilic substitution from the respective mesylate precursor, and its biodistribution was assessed in healthy rats. Permanent occlusion of the middle cerebral artery (MCA) was induced in mice, and small-animal PET was performed 24 h later. RESULTS: Efficient radiolabeling of ML-10 with (18)F was achieved. Biodistribution studies with (18)F-ML-10 revealed rapid clearance from blood (half-life of 23 min), a lack of binding to healthy tissues, and rapid elimination through the kidneys. No significant tracer metabolism in vivo was observed. Clear images of distinct regions of increased uptake, selectively in the ischemic MCA territory, were obtained in the in vivo small-animal PET studies. Uptake measurements ex vivo revealed 2-fold-higher uptake in the affected hemisphere and 6- to 10-fold-higher uptake in the region of interest of the infarct. The cerebral uptake of (18)F-ML-10 was well correlated with histologic evidence of cell death. The tracer was retained in the stroke area but was cleared from blood and from intact brain areas. CONCLUSION: (18)F-ML-10 is useful for noninvasive PET of neurovascular histopathology in ischemic cerebral stroke in vivo. Such an assessment may assist in characterization of the extent of stroke-related cerebral damage and in the monitoring of disease course and effect of treatment.


Subject(s)
Apoptosis , Methylmalonic Acid/analogs & derivatives , Molecular Probe Techniques , Neurons/diagnostic imaging , Neurons/metabolism , Positron-Emission Tomography/methods , Stroke/diagnostic imaging , Stroke/metabolism , Animals , Disease Models, Animal , Male , Methylmalonic Acid/pharmacokinetics , Radiopharmaceuticals/pharmacokinetics , Rats , Stroke/pathology
5.
J Inherit Metab Dis ; 16(1): 147-53, 1993.
Article in English | MEDLINE | ID: mdl-8487494

ABSTRACT

The effects of methylmalonate (MMA) on succinate dehydrogenase (SDH) and beta-hydroxybutyrate dehydrogenase (HBDH) activities in brain and liver of 15-day-old rats were studied. The apparent Km of SDH for succinate was 0.45 mmol/L in brain and 0.34 mmol/L in liver. MMA inhibited the enzyme activity in both tissues with Ki values of 4.5 mmol/L and 2.3 mmol/L in brain and liver, respectively, and the inhibition was of the reversible competitive type. The calculated Km for HBDH with beta-hydroxybutyrate as substrate was 1.26 mmol/L in brain and 0.36 mmol/L in liver. MMA inhibited the enzyme with a Ki value of 0.015 mmol/L in brain and 0.275 mmol/L in liver. These results are probably relevant to our understanding of cerebral metabolism in methylmalonic acidaemic children, especially during ketoacidotic and hypoglycaemic crises, and may be related to the pathogenesis of cerebral dysfunction of methylmalonic acidaemia.


Subject(s)
Brain/drug effects , Hydroxybutyrate Dehydrogenase/antagonists & inhibitors , Liver/drug effects , Methylmalonic Acid/pharmacology , Succinate Dehydrogenase/antagonists & inhibitors , Animals , Animals, Suckling , Brain/enzymology , Brain/growth & development , Liver/enzymology , Liver/growth & development , Methylmalonic Acid/pharmacokinetics , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL
...